Anzeige
Erschienen in:
01.04.2018 | Original article
Effects of topiroxostat in hyperuricemic patients with chronic kidney disease
Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2018
Einloggen, um Zugang zu erhaltenAbstract
Background
Hyperuricemia is associated with chronic kidney disease (CKD). Although topiroxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has a strong effect against hyperuricemia, limited data are available on its renoprotective effect against CKD.
Methods
This study was conducted between October 2014 and May 2016. Thirty patients (20 male, 10 female) were administered 40 mg/day of topiroxostat twice daily. All patients were followed for a year. To elucidate the effects of topiroxostat, we evaluated the clinically documented primary indication of progression, viz. laboratory evidence of kidney function decline (reference indicator), uric acid, and hypertension in different patient groups, separated according to their baseline uProt levels and baseline eGFR.
Results
Topiroxostat treatment resulted in significant reduction in SUA (−1.53 mg/dL), systolic blood pressure (−8.9 mmHg), diastolic blood pressure (−5.0 mmHg), and urinary protein excretion (−795.5 mg/gCr) compared with baseline values. However, serum creatinine and urinary NAG levels, and estimated glomerular filtration rate did not change significantly.
Conclusions
Topiroxostat reduced SUA levels effectively and may exhibit renoprotective effect in hyperuricemic patients with CKD. Further studies are required to clarify whether topiroxostat prevents the progression of renal disease and improves the prognosis of CKD patients.